{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:06:46Z","timestamp":1788876406258,"version":"build-2803163510"},"reference-count":53,"publisher":"American Chemical Society (ACS)","issue":"35","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose: Dipeptidyl peptidase-IV (DPP-IV) is a validated therapeutic target for type 2 diabetes mellitus due to its role in incretin hormone degradation. This study aimed to identify novel small-molecule DPP-IV inhibitors from the ECBD database using an integrated virtual screening and molecular dynamics (MD) approach, acknowledging that experimental validation is necessary to confirm biological activity. Methods: Structure-based virtual screening of 5,500 ECBD compounds was performed using molecular docking to identify high-affinity ligands, followed by interaction analysis with key catalytic residues. Pharmacokinetic suitability was evaluated through in-silico ADMETox profiling. The top-ranked hits were further subjected to 100 ns MD simulations to assess complex stability and conformational effects on the DPP-IV active site. Binding free energies were calculated using the MM\/GBSA method, and docking reliability was validated through redocking experiments. Results and Discussion: Five compounds EOS34295, EOS4915, EOS9480, EOS2567, and EOS62725 exhibited stronger noncovalent binding affinities than vildagliptin and formed stable interactions with essential residues, including GLU205, GLU206, ASN710, and PHE357. ADMETox predictions indicated favorable oral drug-likeness. MD simulations revealed stable protein\u2013ligand complexes, with lower RMSD values for the hit ligands (1.20\u20131.51 \u00c5) compared with vildagliptin (1.90 \u00c5). RMSF analysis showed consistent flexibility without destabilizing fluctuations. Additional hydrogen-bond interactions with PHE357 emerged during MD simulations, indicating enhanced binding persistence. MM\/GBSA analysis confirmed stronger binding energies for EOS34295 (\u221256.58 kcal\/mol), EOS62725 (\u221237.90 kcal\/mol), and EOS2567 (\u221231.27 kcal\/mol) relative to vildagliptin (\u221223.88 kcal\/mol). Conclusion: This study identifies EOS34295, EOS2567, and EOS62725 emerged as promising DPP-IV inhibitory hits with superior binding stability, supporting their potential as antidiabetic leads for future experimental validation.<\/jats:p>","DOI":"10.1021\/acsomega.5c13626","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T23:28:53Z","timestamp":1788132533000},"page":"52439-52451","source":"Crossref","is-referenced-by-count":0,"title":["In Silico Identification\nof Novel Leads as Potential\nDPP-IV Inhibitors as Antidiabetic Agents Using Virtual Screening"],"prefix":"10.1021","volume":"11","author":[{"given":"Milendra Kumar","family":"Turkar","sequence":"first","affiliation":[{"name":"Rajiv Gandhi Proudyogiki Vishwavidyalaya , , Airport Rd, Gandhi Nagar , , ,","place":["Bhopal, Madhya Pradesh, India, 462033"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Ahirwar","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Proudyogiki Vishwavidyalaya , , Airport Rd, Gandhi Nagar , , ,","place":["Bhopal, Madhya Pradesh, India, 462033"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishika","family":"Sahu","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Proudyogiki Vishwavidyalaya , , Airport Rd, Gandhi Nagar , , ,","place":["Bhopal, Madhya Pradesh, India, 462033"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Bhadane","sequence":"additional","affiliation":[{"name":"University of Turku , , Kiinamyllynkatu 10 , ,","place":["Turku, Finland, FI-20520"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra Kumar","family":"Jain","sequence":"additional","affiliation":[{"name":"Lakshmi Narain College of Pharmacy , Kalchuri Nagar, Raisen Road , ,","place":["Bhopal, India, 462021"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2117-5694","authenticated-orcid":true,"given":"Deepti","family":"Jain","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Proudyogiki Vishwavidyalaya , , Airport Rd, Gandhi Nagar , , ,","place":["Bhopal, Madhya Pradesh, India, 462033"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2026090809082018200_cit1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115734","article-title":"Diabetes mellitus: Classification,\nmediators, and complications; A gate to identify potential targets\nfor the development of new effective treatments","volume":"168","author":"Antar","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"2026090809082018200_cit2","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s12325-025-03185-9","article-title":"Diabetes\nMellitus and\nAssociated Vascular Disease: Pathogenesis, Complications, and Evolving\nTreatments","volume":"42","author":"Islam","year":"2025","journal-title":"Adv. Ther."},{"key":"2026090809082018200_cit3","doi-asserted-by":"crossref","unstructured":"Diagnosis and classification\nof diabetes mellitus.  Diabetes Care, 2009. 32 (Suppl 1), : S62\u20137.","DOI":"10.2337\/dc09-S062"},{"issue":"3","key":"2026090809082018200_cit4","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2004","article-title":"Diabetes mellitus, the fastest growing\nglobal public health concern: Early detection should be focused","volume":"7","author":"Hossain","year":"2024","journal-title":"Health Sci. Rep"},{"issue":"4","key":"2026090809082018200_cit5","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1107-y","article-title":"Epidemiology of Diabetes Mellitus and Cardiovascular\nDisease","volume":"21","author":"Glovaci","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"2026090809082018200_cit6","unstructured":"International Diabetes Federation, A.\n          . Atlas, I. D.IDF Diabetes Atlas, 11th ed.2025https:\/\/diabetesatlas.org\/11."},{"key":"2026090809082018200_cit7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional\ndiabetes prevalence estimates for 2019 and projections for 2030 and\n2045: Results from the International Diabetes Federation Diabetes\nAtlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin Pract."},{"issue":"15","key":"2026090809082018200_cit8","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35191","article-title":"Identification of potential\ndipeptidyl peptidase IV inhibitors from the ConMedNP library by virtual\nscreening, and molecular dynamics methods","volume":"10","author":"Fofack","year":"2024","journal-title":"Heliyon"},{"key":"2026090809082018200_cit9","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.2147\/DMSO.S319895","article-title":"A Review of Current Trends with Type\n2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future\nPerspectives","volume":"Volume 14","author":"Reed","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"1","key":"2026090809082018200_cit10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis,\nprevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduction\nTargeted Ther."},{"key":"2026090809082018200_cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2025.100652","article-title":"Diabetes mellitus: Complications,\nemerging therapeutic targets, and evolving treatment approaches","volume":"58","author":"Mohd","year":"2025","journal-title":"Obes. Med."},{"issue":"11","key":"2026090809082018200_cit12","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management\nof Hyperglycemia\nin Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes\nAssociation (ADA) and the European Association for the Study of Diabetes\n(EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"2026090809082018200_cit13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1\nreceptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduction Targeted Ther."},{"issue":"S3","key":"2026090809082018200_cit14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins ( GIP and GLP\n-1) in metabolic and\ncardiovascular disease: A pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes, Obes. Metab."},{"issue":"3","key":"2026090809082018200_cit15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7570\/jomes21053","article-title":"Incretin Hormones: Pathophysiological\nRisk Factors and Potential Targets for Type 2 Diabetes","volume":"30","author":"Rosenberg","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"key":"2026090809082018200_cit16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2020.05.008","article-title":"Insights into incretin-based\ntherapies for treatment of diabetic dyslipidemia","volume":"159","author":"Stemmer","year":"2020","journal-title":"Adv. Drug Delivery Rev."},{"issue":"1","key":"2026090809082018200_cit17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejphar.2010.06.001","article-title":"RBx-0597,\na potent,\nselective and slow-binding inhibitor of dipeptidyl peptidase-IV for\nthe treatment of type 2 diabetes","volume":"652","author":"Singh","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"2026090809082018200_cit18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl\nPeptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical\nbiology and mechanisms of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"issue":"9","key":"2026090809082018200_cit19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1517\/13543784.13.9.1091","article-title":"Inhibitors of dipeptidyl peptidase\nIV: a novel approach for the prevention and treatment of Type 2 diabetes?","volume":"13","author":"Deacon","year":"2004","journal-title":"Expert Opin. Invest. Drugs"},{"key":"2026090809082018200_cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2025.102037","article-title":"Type 2 diabetes\nmellitus \u2013\nconventional therapies and future perspectives in innovative treatment","volume":"42","author":"Gieroba","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"issue":"1","key":"2026090809082018200_cit21","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01623-w","article-title":"GLP-1-based\ntherapies\nfor type 2 diabetes: from single, dual and triple agonists to endogenous\nGLP-1 production and L-cell differentiation","volume":"17","author":"Movahednasab","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"issue":"8","key":"2026090809082018200_cit22","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1007\/s12325-025-03257-w","article-title":"GLP-1\nReceptor Agonists,\nDPP-4 Inhibitors and the Skin\u2500Diabetes Meets Dermatology: A\nBrief Narrative Review","volume":"42","author":"Pantazopoulos","year":"2025","journal-title":"Adv. Ther."},{"issue":"2","key":"2026090809082018200_cit23","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3100","article-title":"Diabetes pharmacotherapy\nand effects on the musculoskeletal system","volume":"35","author":"Kalaitzoglou","year":"2019","journal-title":"Diabetes\nMetab Res. Rev."},{"issue":"12","key":"2026090809082018200_cit24","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia\nin Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes\nAssociation (ADA) and the European Association for the Study of Diabetes\n(EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"2026090809082018200_cit25","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1210\/endrev\/bnad016","article-title":"Treating the Side Effects\nof Exogenous Glucocorticoids; Can We Separate the Good From the Bad?","volume":"44","author":"Pofi","year":"2023","journal-title":"Endocrine Rev."},{"issue":"D1","key":"2026090809082018200_cit26","doi-asserted-by":"publisher","first-page":"D1383","DOI":"10.1093\/nar\/gkae904","article-title":"ECBD:\nEuropean chemical biology database","volume":"53","author":"S\u030ckuta","year":"2025","journal-title":"Nucleic\nAcids Res."},{"issue":"4","key":"2026090809082018200_cit27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/jcc.540110405","article-title":"Macromodel\u2500an integrated software system for modeling organic\nand bioorganic molecules using molecular mechanics","volume":"11","author":"Mohamadi","year":"1990","journal-title":"J. Comput. Chem."},{"issue":"7","key":"2026090809082018200_cit28","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: Improving Force Field Accuracy\non Challenging Regimes of Chemical Space","volume":"17","author":"Lu","year":"2021","journal-title":"J.\nChem. Theory Comput"},{"issue":"1","key":"2026090809082018200_cit29","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.2","article-title":"A comparative study\nof the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory\nactivity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin,\nlinagliptin, saxagliptin, sitagliptin and vildagliptin in mice","volume":"1","author":"Berger","year":"2018","journal-title":"Endocrinol. Diabetes Metabol."},{"issue":"2","key":"2026090809082018200_cit30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: Consistent Treatment of Internal and Surface Residues in\nEmpirical pKa Predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theory Comput."},{"issue":"21","key":"2026090809082018200_cit31","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide:\ndocking and scoring incorporating a model of hydrophobic enclosure\nfor protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"2026090809082018200_cit32","doi-asserted-by":"crossref","unstructured":"Bowers, K. J.; et al.\n          Scalable\nAlgorithms for Molecular Dynamics Simulations on Commodity Clusters; Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing, Association for Computing Machinery: Tampa, FL, 200684-es.","DOI":"10.1145\/1188455.1188544"},{"issue":"14","key":"2026090809082018200_cit33","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27144391","article-title":"In-Silico Screening\nand Molecular Dynamics Simulation of Drug Bank Experimental Compounds\nagainst SARS-CoV-2","volume":"27","author":"Alturki","year":"2022","journal-title":"Molecules"},{"issue":"43","key":"2026090809082018200_cit34","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and Dynamics of the TIP3P, SPC, and SPC\/E\nWater Models at 298 K","volume":"105","author":"Mark","year":"2001","journal-title":"J. Phys. Chem. A"},{"issue":"8","key":"2026090809082018200_cit35","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1063\/1.449071","article-title":"The Nose\u2013Hoover\nthermostat","volume":"83","author":"Evans","year":"1985","journal-title":"J. Chem. Phys."},{"issue":"18","key":"2026090809082018200_cit36","doi-asserted-by":"publisher","DOI":"10.1063\/5.0193281","article-title":"Novel barostat implementation\nfor molecular dynamics","volume":"160","author":"Janek","year":"2024","journal-title":"J. Chem. Phys."},{"issue":"12","key":"2026090809082018200_cit37","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: A new molecular\ndynamics method","volume":"52","author":"Parrinello","year":"1981","journal-title":"J. Appl. Phys."},{"issue":"8","key":"2026090809082018200_cit38","doi-asserted-by":"publisher","DOI":"10.1063\/1.5129393","article-title":"The u-series: A separable\ndecomposition for electrostatics computation with improved accuracy","volume":"152","author":"Predescu","year":"2020","journal-title":"J. Chem. Phys."},{"key":"2026090809082018200_cit39","unstructured":"Turner, P. J.; C.f.c., O.G.I.o.S. land-margin research, and B. Technology, OR..  XMGRACE, Version\n5.1. 192005; Vol. 2(5), , p 19."},{"issue":"1","key":"2026090809082018200_cit40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-46463-4","article-title":"Computational identification\nof a marine derived dual inhibitor for type 2 diabetes mellitus using\nintegrated in silico approaches","volume":"16","author":"Biswas","year":"2026","journal-title":"Sci. Rep."},{"key":"2026090809082018200_cit41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lddd.2026.100408","article-title":"Computational identification\nof novel DPP-4 inhibitors based on QSAR modeling, molecular docking,\nand molecular dynamics simulations","volume":"23","author":"Shi","year":"2026","journal-title":"Lett. Drug\nDes. Discovery"},{"key":"2026090809082018200_cit42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116834","article-title":"Discovery\nof the selective\nand nanomolar inhibitor of DPP-4 more potent than sitagliptin by structure-guided\nrational design","volume":"279","author":"Mobeen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"2026090809082018200_cit43","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3897\/pharmacia.69.e95096","article-title":"Design, synthesis and anti-diabetic activity\nof piperazine sulphonamide derivatives as dipeptidyl peptidase-4 inhibitors","volume":"69","author":"Kalli","year":"2022","journal-title":"Pharmacia"},{"issue":"4","key":"2026090809082018200_cit44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2165\/00003495-200767040-00007","article-title":"Sitagliptin","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"issue":"11","key":"2026090809082018200_cit45","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety\nof the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy\nin patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"issue":"9","key":"2026090809082018200_cit46","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/dom.14061","article-title":"Efficacy and safety of evogliptin treatment\nin patients with type 2 diabetes: A multicentre, active-controlled,\nrandomized, double-blind study with open-label extension (the EVERGREEN\nstudy)","volume":"22","author":"Kim","year":"2020","journal-title":"Diabetes, Obes. Metab."},{"issue":"17","key":"2026090809082018200_cit47","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s40265-015-0496-5","article-title":"Evogliptin:\nFirst Global Approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"2026090809082018200_cit48","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/DMSO.S106133","article-title":"Teneligliptin in management\nof type 2 diabetes mellitus","volume":"9","author":"Sharma","year":"2016","journal-title":"Diabetes Metab.\nSyndr. Obes."},{"key":"2026090809082018200_cit49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/DMSO.S35682","article-title":"Teneligliptin:\na DPP-4 inhibitor for the treatment of type 2 diabetes","volume":"6","author":"Kishimoto","year":"2013","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"7","key":"2026090809082018200_cit50","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.bmcl.2007.01.026","article-title":"Pyrrolidine-constrained\nphenethylamines: The design of potent, selective, and pharmacologically\nefficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like\nscreening hit","volume":"17","author":"Backes","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"13","key":"2026090809082018200_cit51","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:\na potent, selective, and orally bioavailable dipeptidyl peptidase\nIV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J. Med. Chem."},{"issue":"23","key":"2026090809082018200_cit52","doi-asserted-by":"publisher","first-page":"7418","DOI":"10.1016\/j.bmc.2013.09.048","article-title":"Synthesis and biological\nevaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile\nderivatives as dipeptidyl peptidase-4 inhibitors for the treatment\nof type 2 diabetes","volume":"21","author":"Wang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"2026090809082018200_cit53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2025.141707","article-title":"Design, discovery, molecular\ndocking, dynamics and in-silico ADME-T evaluation of novel hybrids\nof 1,3,5-triazine-morpholino-thiazine as an anti-diabetic agent in\nWistar rats via inhibition of DPP-4","volume":"1345","author":"Gupta","year":"2025","journal-title":"J. Mol.\nStruct."}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.5c13626","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/35\/52439\/67343492\/acsomega.5c13626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/35\/52439\/67343492\/acsomega.5c13626.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:08:30Z","timestamp":1788872910000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/11\/35\/52439\/5323251\/In-Silico-Identification-of-Novel-Leads-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":53,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.5c13626","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}